Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: An observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia - Sun - 2021 - Cancer Medicine - Wiley Online Library
Palbociclib–fulvestrant combo yields overall survival gains in advanced breast cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
Current Oncology | Free Full-Text | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer - The Breast
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study - ScienceDirect
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL
Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice | PLOS ONE
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Semantic Scholar
View PDF
Ribociclib Improves Survival in Advanced Breast Cancer - NCI
Comparative effectiveness of first line palbociclib plus letrozole vs. letrozole alone for hormone-receptor positive metastatic breast cancer in real world clinical practice - BJMO
Progression-free survival for palbociclib plus letrozole by line of... | Download Scientific Diagram
Final analysis of progression-free survival in the PALOMA-3 study... | Download Scientific Diagram
Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor‑positive and human epidermal growth factor receptor 2‑negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia
NEJM on Twitter: "Original Article: Overall Survival with Palbociclib and Fulvestrant in Advanced #BreastCancer (PALOMA-3) https://t.co/PoifcpQnQc Visit the @NEJMGroup booth (Hall B1, booth P-109) for a copy of this study and other
IBRANCE 75 mg hard capsules - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text
Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL
Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy - Tam Binh V Bui, Desirée MT Burgers, Mariette J Agterof, Ewoudt
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer - Gelmon - 2020 - The Breast Journal -
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
